Full spectrum anti-dengue antibody
AssigneeMassachusetts Institute of Technology
InventorsRam Sasisekharan, Kannan Tharakaraman
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
Claims11
An antibody agent that:
- (a) has a heavy chain variable region that shows at least 95% substantial sequence homology with that of heavy chain variable region of 4E5A (SEQ ID NO. 29) and a light chain variable region that shows at least 95% substantial sequence homology with that of light chain variable region of 4E5A (SEQ ID NO. 30);
- and
- (b) its heavy chain comprises one or more of the following mutations relative to 4E5A:
- VH_S26_del;
- and
- VH_G27_del or
- VH_G27A.
A method of treating a subject, the method comprising a step of:
- administering to a subject suffering from or susceptible to Dengue virus an antibody agent that:
- (a) has a heavy chain variable region that shows at least 95% substantial sequence homology with that of heavy chain variable region of 4E5A (SEQ ID NO. 29) and a light chain variable region that shows at least 95% substantial sequence homology with that of light chain variable region of 4E5A (SEQ ID NO. 30);
- and
- (b) its heavy chain comprises one or more of the following mutations relative to 4E5A:
- VH_S26_del;
- and
- VH_G27_del or
- VH_G27A.
Dependencies are inferred from the claim text.